Abstract
Background: In patients with IPF exercise intolerance is often associated with hypoxemia. Therefore, SOT may be offered. The Oxymizer® is a nasal cannula incorporating an internal reservoir with the potential to deliver higher oxygen (O2) doses to the patient on the same O2-flow compared to a conventional nasal cannula (CNC).
Objectives: Primary aim was to investigate the effects of SOT delivered via Oxymizer compared to a CNC in hypoxemic IPF-patients on walking capacity. Secondary aim was to evaluate the effects on O2-saturation (SpO2), heart- and breathing rate at isotime (end of shortest endurance shuttle walk test; ESWT).
Methods: 26 patients with a confirmed diagnosis of IPF and SOT-indication during exercise were consecutively included in this trial. After an initial incremental shuttle walk test, patients performed, in randomized order and with a 24h-resting period between tests, two ESWTs - one with Oxymizer and one with CNC.
Results: 22 patients (70±7years; VC:54±15%/pred) completed all tests. Walking capacity was significantly greater while using the Oxymizer compared to CNC (523±369vs.419±332sec, p=0.027). 15 patients (68%) walked longer with the Oxymizer. At isotime, SpO2 (81.6±8.8 vs.78.5±8.1%, p=0.001) was significantly higher while heart- (112±16vs.118±13bpm) and breathing rate (38±8vs.41±8bpm) were significantly (p<0.05) lower using the Oxymizer.
Conclusion: SOT when provided by the Oxymizer showed significant and clinically relevant benefits on walking capacity in IPF-patients by improving physiological parameters. However, only 8 (36%) patients would prefer the Oxymizer for their daily use.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, OA3573.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019